Logo

Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma

Share this

Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The P-III CLEAR study involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg- IV- q3w) or in combination with everolimus (5mg- qd) vs sunitinib (50 mg- q4w) in 1-069 patients for the 1L treatment with advanced RCC
  • The trial met its 1EPs with Keytruda + Lenvima shows 61% reduction in the risk of disease progression or death- mPFS (2yrs. vs 9 mos.) 2 EPs shows 34% reduced the risk of death- ORR (71.0% vs 36.1%); CR (16.1 vs 4.2%); PR( 54.9% vs 31.9%); mDoR(25.8 vs 14.6mos)
  • Lenvima + everolimus shows 35% reduction in the risk of disease progression or death; mPFS (14.7 vs 9.2mos); CR (9.8% vs 4.2%); PR (43.7% vs 36.1%); mDOR (16.6 vs 14.6 mos.)@median follow-up 27 mos.

 ­ Ref: Merck | Image: Merck 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions